Financials data is unavailable for this security.
View more
Year on year 10X Genomics Inc had net income fall 53.67% from a loss of 166.00m to a larger loss of 255.10m despite a 19.81% increase in revenues from 516.41m to 618.73m. An increase in the cost of goods sold as a percentage of sales from 23.31% to 33.85% was a component in the falling net income despite rising revenues.
| Gross margin | 66.63% |
|---|---|
| Net profit margin | -28.99% |
| Operating margin | -31.74% |
| Return on assets | -19.36% |
|---|---|
| Return on equity | -24.87% |
| Return on investment | -21.99% |
More ▼
Cash flow in USDView more
In 2023, 10X Genomics Inc increased its cash reserves by 58.03%, or 131.93m. Cash Flow from Investing totalled 133.49m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 15.20m for operations while cash generated from financing totalled 13.67m.
| Cash flow per share | -1.22 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.97 |
|---|---|
| Tangible book value per share | 5.80 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.90 |
|---|---|
| Quick ratio | 4.12 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
